UNIVERSITY OF KENT
MODULE SPECIFICATION TEMPLATE
1. Title of the module
PHAM 1008 Pharmacology and Therapeutics I
2. School which will be responsible for management of the module
Medway School of Pharmacy
3. Start date of the module
Autumn 2010
4. The cohort of students (onwards) to which the module will be applicable
Students in the second year of the MPharm (Hons) programme
5. The number of students expected to take the module
150
6. Modules to be withdrawn on the introduction of this proposed module and consultation with other relevant Schools and Faculties regarding the withdrawal
None
7. Level of the module (e.g. Certificate [C], Intermediate [I], Honours [H] or Postgraduate [M])
Intermediate [I]
8. The number of credits which the module represents
30 credits
9. Which term(s) the module is to be taught in (or other teaching pattern)
Terms 1 and 2
10. Prerequisite and co-requisite modules
PHAM 1003 (Introduction to Physiology and Pharmacology); MPharm students will also take PHAM 1056 (Pharmacology and Therapeutics 2)
11. The programme(s) of study to which the module contributes
Master of Pharmacy (MPharm)
12. The intended subject specific learning outcomes and, as appropriate, their relationship to programme learning outcomes
On successful completion of this module, students will have demonstrated:
1. a knowledge and understanding of the underlying genetic, immunological and pathological basis of selected diseases.(PO16, PO19, PO21)
2. a knowledge and critical understanding of non-pharmacological interventions and their role in the prevention and management of selected diseases.(PO25)
3. a knowledge and critical understanding of the pharmacological interventions which are appropriate for the prevention and/or treatment of selected conditions (PO4, PO6, PO16-22)
4. an ability to reflect on and discuss detailed mechanisms of drug action as well as the cautions, contra-indications and risks associated with certain drug therapies.(PO4 PO6, PO8, PO 17-25)
5. an ability to undertake patient monitoring and critically evaluate the appropriateness and limitations of tests undertaken linked to selected clinical conditions and /or therapeutic interventions. (PO27, PO28, PO53, PO56)
13. The intended generic learning outcomes and, as appropriate, their relationship to programme learning outcomes
1. Ability to retrieve and evaluate information from primary, secondary and tertiary sources including on line searches. (PO61, PO62, PO67)
2. Ability to demonstrate and apply knowledge (PO38, PO39, PO59,)
3. Interpretation of patient clinical lab data (PO45, PO61)
4. Problem recognition and problem solving (PO40, PO41, PO44, PO59, PO60)
5. Written and oral communication skills (PO43, PO57)
6. IT skills (PO63)
7. Independent study skills (PO65)
14. A synopsis of the curriculum
This module aims to provide students with an in-depth knowledge and critical understanding of pathophysiology of selected body systems. These diseases will be studied in-depth including epidemiology, aetiology, clinical presentation, diagnostic criteria, aims of management, non-pharmacological and pharmacological management (detailed mechanism of action) and factors which influence therapeutic options including co-morbidity, drug interactions, effectiveness and toxicity.
Gastrointestinal
· Dyspepsia
· Gastro-oesophageal disease (GORD)
· Peptic ulcer disease
· Motility disorders – constipation, diarrhoea and irritable bowel syndrome
· Irritable bowel syndrome
Respiratory
· Asthma
· Chronic obstructive pulmonary disease
· Rhinitis
Cardiovascular
· Hypertension - primary and secondary prevention
· Hyperlipidaemia – primary and secondary prevention
· Atherosclerosis and ischaemic heart disease including angina and myocardial infarction
· Arrhythmias
· Haemostasis and thrombosis - antiplatelets, anticoagulants, thrombolytics and antifibrinolytics
· Heart failure
Hepatic
· Liver- structure and functions
· Classification of liver disease
· Causes of liver disease
· Assessment of liver function
· Signs and symptoms of liver disease
· Complications of liver disease
· Mechanisms of drug induced liver disease
· Characteristics of drug induced liver disease
· Types of liver injury and liver function tests
· Prevention and treatment of drug induced liver disease
· Role of the pharmacist in drug induced liver disease
Musculoskeletal
· Osteoarthritis
· Rheumatoid arthritis
· Gout
· Osteoporosis
Ophthalmology
· Glaucoma
Renal
· Diuretic drugs
· Acute renal failure
· Chronic renal failure
· Assessment of renal function
· Nephrotoxic drugs
15. Indicative Reading List
ISBN Number / Author / Date / Title / Publisher0323035698* / Page, C.B., Curtis, M., Walker, M., and Hoffman, B. / 2006 / Integrated Pharmacology, 3rd Edition / Mosby
443071454* / Rang H.P., Dale M.M., Ritter J.M., Moore, P.K. & Lamb, P. / 2007 / Pharmacology 6th Edition / Churchill Livingstone
978-0-07-160405-5 / Katzung, Masters & Trevor. / 2009 / Basic and Clinical Pharmacology / McGraw Hill
* These books are also on the suggested reading list for stage 1 (PHAM 1003) and stage 2 (PHAM 1056 & PHAM 1008)
16. Learning and Teaching Methods, including the nature and number of contact hours and the total study hours which will be expected of students, and how these relate to achievement of the intended learning outcomes
The module will be delivered using a variety of teaching methods to enable students to meet all the specific learning outcomes (SSLO 12.1 - 12.5) and to acquire knowledge, communication (both written and oral), problem solving and clinical skills. These methods include didactic lectures, practical/workshop sessions, patient simulation (role play, paper-based case studies presentations, guided group discussions, computerized patient simulation)
Students are also expected to undertake hours of managed student centred learning (MSCL) activities and engage in private study.
Seminars will constitute interim assessment feedback sessions and revision seminars. The two interim feedback seminar sessions are designed to provide students with feedback on MCQs and discuss techniques on answering such questions.
Revision seminars will be delivered to support students with the review of all material covered in the module to prepare them for the final examination.
Summary of Learning and Teaching Activities
Lecture / Practical / MSCL/ CAL / Seminars / Private Study / Formal assessment / Total hours45 / 36 / 90 / 6 / 117 / 6 / 300
Directed Learning and Teaching Activities
Activity / Lecture / Practical/ workshops / MSCLRenal / 6 / 1 x 3h / 12
Respiratory / 6 / 1 x 3h / 12
Ophthalmology / 2 / 1 x 3h / 4
Cardiovascular / 13 / 3 x 3h / 26
Gastrointestinal / 6 / 2 x 3h / 12
Hepatic / 6 / 2 x 3h / 12
Musculoskeletal / 6 / 1 x 3h / 12
Practice OSCE / 1 x 3h
Seminars
Formal assessment
Total hours / 45 / 36 / 90
Attendance at scheduled sessions
Satisfactory attendance and performance is required at all scheduled coursework sessions (excluding lectures). This is defined as a minimum of 80% attendance at all classes excluding lectures plus lab books/worksheets maintained to a required standard.
Attendance of less than 80% will result in a capped continuous assessment mark unless a concession form supported by medical evidence is completed in accordance with the School guidelines.
17. Assessment methods and how these relate to testing achievement of the intended learning outcomes
A variety of assessment methods will be used to assess students’ knowledge, communication (both written and oral), problem solving and clinical skills.
These include multiple choice questions (MCQs), an objective structured clinical examination (OSCE) and a final exam
Continuous Assessment 40%
SSLO12.1 - SSLO5 will be assessed by 2 interim assessments consisting of multiple choice questions (2x25%)
SSLO12.5 will be assessed by a one-hour Objective Structured Clinical Examination (OSCE) 50%
SSLO12.1 – SSLO12.5 will be assessed through satisfactory attendance and performance at all scheduled coursework sessions (excluding lectures). This is defined as a minimum of 80% attendance at all sessions (excluding lectures) plus lab books/worksheets maintained to a required standard Pass/Fail
Attendance of less than 80% will constitute a FAIL and will result in a capped continuous assessment mark unless a concession form supported by medical evidence is completed in accordance with the School guidelines.
Examination 60%
SSLO12.1 – SSLO12.5 will be assessed by a 3-hour written examination.
Assessment Details
Methods of Assessment / Learning outcomes assessed / Weighting / Outline DetailsContinuous assessment / All learning outcomes / 25% / Multiple choice questions (MCQs)
Continuous assessment / All learning outcomes / 25% / Multiple choice questions (MCQs)
Continuous assessment / Learning outcome 12.5 / 50% / Objective Structured Clinical Examination (OSCE)
Continuous assessment / All learning outcomes / PASS/FAIL / 80% minimum attendance at all classes excluding lectures plus lab books/worksheets maintained to a required standard
Examination / All learning outcomes / 60% / 1 x 3hr examination
Pass Mark:
The pass mark for this course is 40% overall with a minimum of 35% in both the continuous
assessment and final written examination.
NOTE : Less than 80% attendance at all coursework sessions (excluding lectures) will result in a capping of the continuous assessment mark unless a concession form supported by medical evidence is completed and submitted in accordance with the School guidelines.
18. Implications for learning resources, including staff, library, IT and space
No additional resources are required
19. A statement confirming that as far as can be reasonably anticipated, the curriculum, learning and teaching methods and forms of assessment do not present any nonjustifiable disadvantage to students with disabilities
As far as the Pharmacology and Therapeutics 1 module is concerned, the curriculum, learning and teaching methods and all forms of assessment do not present any non-justifiable disadvantages to students with disabilities
Statement by the School Director of Learning and Teaching: "I confirm I have been consulted on the above module proposal and have given advice on the correct procedures and required content of module proposals"
Dr Buge Apampa......Director of Learning and Teaching
DR BUGE APAMPA……………
Print Name / 17 September 2010......
Date
Statement by the Head of School: "I confirm that the School has approved the introduction of the module and, where the module is proposed by School staff, will be responsible for its resourcing"
Professor Cumming......Head of School
PROFESSOR CUMMING……………….
Print Name / 17 September 2010......
Date
1